Evaluating a patient with chest pain? Which will you choose?

Please consider the PROMISE trial for patients meeting the following eligibility criteria.

inclusion criteria
1. New or worsening chest pain or equivalent symptoms suspicious for clinically significant CAD
2. No prior evaluation for this episode of symptoms
3. Planned non-invasive testing for diagnosis
4. Men age \( \geq 55 \) years and women age \( \geq 65 \), with or without risk factors
5. If age in men 45–54 or women 50–64 years, must have increased probability of CAD due to either:
   A. Diabetes requiring medical treatment OR Peripheral arterial disease (\( \geq 50\% \)) peripheral arterial stenosis treated medically or invasively OR cerebrovascular disease [stroke, documented \( \geq 50\% \) carotid stenosis treated medically or invasively]
   OR
   B. At least 1 of the following cardiovascular risk factors:
   - Ongoing tobacco use
   - Hypertension
   - Abnormal ankle-brachial index < 0.9
   - Dyslipidemia
6. Serum creatinine \( \leq 1.5 \) mg/dL within past 90 days
7. Negative urine/serum pregnancy test for female subjects of child-bearing potential

exclusion criteria
1. Diagnosed or suspected acute coronary syndrome requiring hospitalization or urgent or emergent testing; elevated troponin or CK-MB
2. Hemodynamically or clinically unstable condition (systolic BP < 90 mm Hg, atrial or ventricular arrhythmias, or persistent resting chest pain felt to be ischemic despite adequate therapy)
3. Known CAD with prior MI, PCI, CABG or any angiographic evidence of CAD \( \geq 50\% \) lesion in a major epicardial vessel
4. Any invasive coronary angiography or non-invasive anatomic or functional CV test for detection of CAD, including CTA and exercise ECG, within previous 12 months
5. Known significant congenital, valvular (\( \geq \) moderate) or cardiomyopathic process (hypertrophic cardiomyopathy or reduced systolic left ventricular function [LVEF \( \leq 40\% \)]) which could explain cardiac symptoms
6. Contraindication to undergoing a CTA, including but not limited to:
   a. Allergy to iodinated contrast agent
   b. Unable to receive beta blockers unless heart rate \( \leq 65 \) bpm
   c. Pregnancy
7. Life expectancy < 2 years
8. Unable to provide written informed consent or participate in long-term follow-up

PROMISE is a prospective, phase 4, pragmatic, randomized trial of clinical effectiveness of imaging strategies, comparing the value of anatomic testing (coronary CT angiography [CTA]) to functional testing (exercise ECG, stress nuclear, stress echo).

To refer potential patients, please contact:

study coordinator
phone number
email address

For more information about the PROMISE study, please visit www.promisetrial.org